Globus Medical Announces ExcelsiusGPS® Milestone: 3,000 screws implanted
Study demonstrates potential to improve spine surgery techniques by combining robotics and navigation
AUDUBON, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today a new clinical milestone with the successful implantation of over 3,000 screws using ExcelsiusGPS®, the company’s revolutionary robotic guidance and navigation system. Since the launch of ExcelsiusGPS® in late 2017, orthopedic and neurosurgeons have used the system with three compatible imaging modalities (preoperative CT, intraoperative CT, and fluoroscopic imaging) across a variety of spine surgery procedures to minimize radiation exposure, streamline workflow, and assist in screw placement. A recent white paper comparing robotic-assisted versus conventional screw placement demonstrates some of the benefits of this technology.
“Having completed installations and surgeon training programs through the first half of 2018, we see surgeons using this technology in open and minimally invasive spine procedures including posterior cervical fusion, sacroiliac joint fusion, and thoracolumbar fusion with posterior and single position lateral approaches,” said Chief Executive Officer Dave Demski. “Surgeons are realizing the benefits of the ExcelsiusGPS® platform and the potential to significantly improve surgical techniques as demonstrated in the recent cadaveric study.”
The study, led by Dr. Alexander R. Vaccaro, MD, Ph.D, M.B.A and performed by 10 board certified surgeons in a simulated surgical environment, evaluated pedicle screw placement time, accuracy, and radiation dose for ExcelsiusGPS® in open and MIS approaches compared to conventional surgical techniques. Results demonstrated the ExcelsiusGPS® robotic navigation significantly improved pedicle screw accuracy, allowed placement of larger screw diameters and lengths than conventional techniques, and reduced radiation exposure to the clinician. Additionally, ExcelsiusGPS® significantly reduced screw insertion time compared to the conventional MIS technique.
To learn more about the benefits of ExcelsiusGPS®, visit globusmedical.com/ExcelsiusGPS
About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Contact:
Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
